Why the study?
Elucidation of the exact roles of VIP/PACAP and the development of new therapeutic approaches have been limited by a lack of specific pharmacological tools and exact signaling mechanisms.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Should not yet change oncology practice; leaves open translation of receptor signaling insights into therapies.
PURPOSE OF REVIEW: To discuss recent advances of vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating polypeptide (PACAP) receptors in pharmacology, cell biology, and intracellular signaling in cancer. RECENT FINDINGS: Recent studies provide new insights into the pharmacology, cell biology of the VIP/PACAP system and show they play important roles in a number of human cancers, as well as in tumor growth/differentiation and are providing an increased understanding of their signaling cascade that is suggesting new treatment targets/approaches. SUMMARY: Recent insights from studies of VIP/PACAP and their receptors in both central nervous system disorders and inflammatory disorders suggest possible new treatment approaches. Elucidation of the exact roles of VIP/PACAP in these disorders and development of new therapeutic approaches involving these peptides have been limited by lack of specific pharmacological tools, and exact signaling mechanisms involved, mediating their effects. Reviewed here are recent insights from the elucidation of structural basis for VIP/PACAP receptor activation as well as the signaling cascades mediating their cellular effects (using results primarily from the study of their effects in cancer) that will likely lead to novel targets and treatment approaches in these diseases.
No takes yet. Share an insight, caveat, or question.
Moody et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: